Exeliom Biosciences, a Paris, and Dijon, France-based clinical-stage biopharmaceutical company, raised €8m in Series A extension funding.
The round, which brought the total Series A amount to €24M, was led by CE-Ventures, the corporate venture capital platform of Crescent Enterprises, a multinational company headquartered in the United Arab Emirates, joined by existing investors including VCs Auriga Partners, UI Investissement and Capital Grand Est, and Biocodex, an independent multinational pharmaceutical company.
The company intends to use the funds to progress the clinical development of its lead candidate EXL01 into two new therapeutic areas: immuno-oncology and infectious diseases.
Led by CEO Benjamin Hadida, Exeliom Biosciences is a clinical-stage biopharmaceutical company specialized in the development of microbiome-based immunotherapies with a mission to bring innovation to the treatment of inflammatory bowel diseases, cancer, and infectious diseases. Its lead asset, EXL01, a rationally selected, oral biotherapeutic product, is in clinical development for the treatment of Crohn’s disease and will soon also be evaluated in three immuno-oncology combination trials and in a recurrent C. difficile infection trial.
EXL01 is already being evaluated in the clinic in the field of chronic inflammatory bowel diseases, as part of a Phase 1 clinical trial in Crohn’s disease patients. In the first half of 2024, Exeliom Biosciences plans to initiate three Phase 1/2 clinical trials evaluating the combination of EXL01 with standard-of-care treatments (including immune checkpoint inhibitors) in three different cancers: gastric cancer, non-small cell lung cancer and hepatocellular carcinoma.
The company also plans to launch, in parallel, a Phase 1/2 clinical study evaluating EXL01 as an alternative to the current standard treatment (fecal transplantation) for recurrent Clostridium difficile infection.
FinSMEs
20/07/2023